Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc R Theoret

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2017
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic MelanomaAmy Barone, Maitreyee Hazarika, Marc R Theoret, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Considerations for Drug Development in Myelodysplastic SyndromesMikkael A Sekeres, Nina Kim, Amy E DeZern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2022
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to PatientsJeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2023
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and EthnicityDianne Pulte, Laura Fernandes, Guo Wei, et al.
JAMA Oncology|January 6, 2022
Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration DatabaseMitchell S Anscher, Shaily Arora, Chana Weinstock, et al.
Journal of Neuro-Oncology|June 22, 2021
US Food and Drug Administration regulatory updates in neuro-oncologyGautam U Mehta, Amy K Barone, Diana Bradford, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 9, 2004
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destructionDouglas C Palmer, Sanjeeve Balasubramaniam, Ken-Ichi Hanada, et al.
The Oncologist|May 31, 2022
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC TrialE Dianne Pulte, Haiyan Chen, Lauren S L Price, et al.
The Oncologist|March 9, 2021
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung CancerLuckson Mathieu, Sujay Shah, Lee Pai-Scherf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2022
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative TherapyEmily Y Jen, Xin Wang, Meng Li, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2017
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic MelanomaAmy Barone, Maitreyee Hazarika, Marc R Theoret, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Considerations for Drug Development in Myelodysplastic SyndromesMikkael A Sekeres, Nina Kim, Amy E DeZern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2022
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to PatientsJeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2023
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and EthnicityDianne Pulte, Laura Fernandes, Guo Wei, et al.
JAMA Oncology|January 6, 2022
Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration DatabaseMitchell S Anscher, Shaily Arora, Chana Weinstock, et al.
Journal of Neuro-Oncology|June 22, 2021
US Food and Drug Administration regulatory updates in neuro-oncologyGautam U Mehta, Amy K Barone, Diana Bradford, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 9, 2004
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destructionDouglas C Palmer, Sanjeeve Balasubramaniam, Ken-Ichi Hanada, et al.
The Oncologist|May 31, 2022
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC TrialE Dianne Pulte, Haiyan Chen, Lauren S L Price, et al.
The Oncologist|March 9, 2021
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung CancerLuckson Mathieu, Sujay Shah, Lee Pai-Scherf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2022
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative TherapyEmily Y Jen, Xin Wang, Meng Li, et al.
Pageof 11